Targeting CCR8 with anti-CCR8 mAb not only reduced multiclonal Tregs specifically in tumor tissues but also evoked strong anti-tumor immune responses without causing harmful autoimmunity [34, 90, 120, 124]. Here, CCR8 is linked to neoplasm.